US equities |
NVDA $237.41 ▲+1.48% MU $1,058.41 ▼-1.53% SPCX $164.22 ▲+3.31% MSFT $528.04 ▲+2.03% TSLA $374.47 ▲+1.05% INTC $116.56 ▼-2.32% SNDK $1,725.28 ▲+0.31% AMD $630.25 ▼-0.58%
FinancialContent

Articles published by Vir Biotechnology, Inc.

< Previous 1 2 3 4 Next >
News headline image
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces Chief Financial Officer Transition
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Participate in Upcoming Investor Conferences
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces Proposed Public Offering of Common Stock
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
News headline image
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Vir Biotechnology, Inc.
Via Business Wire
Tickers VIR
< Previous 1 2 3 4 Next >